NCT00955435Completed
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15
Proteomic Analysis of the Combined Hormonal Therapy and Radiation Therapy for Localized Prostate Cancer
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This clinical trial is studying blood and urine samples in patients with newly diagnosed localized prostate cancer treated with hormone therapy and radiation therapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 60 (actual)
- First submitted
- 7 Aug 2009
- Start date
- 1 Feb 2006
- Primary completion date
- 26 Jan 2026
- Lead sponsor
- Cancer Trials Ireland
- Diseases
- Prostate cancer
- NCT number
- NCT00955435
What you commit to
- Study type: Observational
- Participants enrolled: 60
- From 1 Feb 2006 to the primary completion date, 26 Jan 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patient has previously received treatment for prostate cancer other than TURP/ TRUS
- The patient has previously received hormonal treatment for prostate cancer
- Treatment with non-approved or investigational drug within 30 days before day one of the trial
Other illness
- The patient has or had other co-existing malignancies within the past 5 years other than non- melanoma skin cancer
Lab values
- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial. In the opinion of the investigator, any evidence of severe or uncontrolled systematic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease
Other
- The patient has had a bilateral orchidectomy
Who the study is looking for
- Age 18 years or over.
- Histologically confirmed invasive adenocarcinoma of the prostate (by TURP or TRUS).
- Localised prostate cancer with a Gleason score 7
- Short term hormonal treatment 4-8 months
- Performance status of KPS ≥ 60 / WHO 0-2
- Absence of distant metastases
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Saint Luke's Radiation Oncology Network Coordinator of this site? Confirm its status | Dublin | Ireland | Unknown status |
| Beacon Hospital Coordinator of this site? Confirm its status | Dublin | Ireland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.